Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma

A. Manetta; P. G. Satyaswarcoop; E. S. Podczaski; T. Hamilton; R. F. Ozols; R. Mortel

Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma

A. Manetta, P. G. Satyaswarcoop, E. S. Podczaski, T. Hamilton, R. F. Ozols, R. Mortel

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The antiproliferative effect of alpha-difluoromethylornithine (DFMO) was investigated in a human ovarian cancer cell line (NIH:OVCAR3) both in vitro and in vivo. DFMO at 5 x 10^-5M, 5 x 10^-4M and 1 x 10^-3M concentrations showed growth inhibition of NIH:OVCAR3 cells in culture. Parallel determination of CA 125 in the culture media of these cells show significant decrease in the presence of DFMO compared to controls. Oral administration of DFMO (2% aqueous solution) to nude mice bearing intraperitoneal tumors resulted in a mean survival of 45 days (38-60) versus 25 days (20-35) for control. Both in vitro and in vivo results suggest that DFMO has potential value in the treatment of ovarian carcinoma and should be considered for clinical trials in appropriate cancer patients.

Original language	English (US)
Pages (from-to)	222-227
Number of pages	6
Journal	European Journal of Gynaecological Oncology
Volume	9
Issue number	3
State	Published - 1988

All Science Journal Classification (ASJC) codes

Oncology
Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{72adfdaf3b8c4d10a7e6195de000cbd0,

title = "Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma",

abstract = "The antiproliferative effect of alpha-difluoromethylornithine (DFMO) was investigated in a human ovarian cancer cell line (NIH:OVCAR3) both in vitro and in vivo. DFMO at 5 x 10-5M, 5 x 10-4M and 1 x 10-3M concentrations showed growth inhibition of NIH:OVCAR3 cells in culture. Parallel determination of CA 125 in the culture media of these cells show significant decrease in the presence of DFMO compared to controls. Oral administration of DFMO (2% aqueous solution) to nude mice bearing intraperitoneal tumors resulted in a mean survival of 45 days (38-60) versus 25 days (20-35) for control. Both in vitro and in vivo results suggest that DFMO has potential value in the treatment of ovarian carcinoma and should be considered for clinical trials in appropriate cancer patients.",

author = "A. Manetta and Satyaswarcoop, {P. G.} and Podczaski, {E. S.} and T. Hamilton and Ozols, {R. F.} and R. Mortel",

year = "1988",

language = "English (US)",

volume = "9",

pages = "222--227",

journal = "European Journal of Gynaecological Oncology",

issn = "0392-2936",

publisher = "MRE Press",

number = "3",

}

TY - JOUR

T1 - Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma

AU - Manetta, A.

AU - Satyaswarcoop, P. G.

AU - Podczaski, E. S.

AU - Hamilton, T.

AU - Ozols, R. F.

AU - Mortel, R.

PY - 1988

Y1 - 1988

N2 - The antiproliferative effect of alpha-difluoromethylornithine (DFMO) was investigated in a human ovarian cancer cell line (NIH:OVCAR3) both in vitro and in vivo. DFMO at 5 x 10-5M, 5 x 10-4M and 1 x 10-3M concentrations showed growth inhibition of NIH:OVCAR3 cells in culture. Parallel determination of CA 125 in the culture media of these cells show significant decrease in the presence of DFMO compared to controls. Oral administration of DFMO (2% aqueous solution) to nude mice bearing intraperitoneal tumors resulted in a mean survival of 45 days (38-60) versus 25 days (20-35) for control. Both in vitro and in vivo results suggest that DFMO has potential value in the treatment of ovarian carcinoma and should be considered for clinical trials in appropriate cancer patients.

AB - The antiproliferative effect of alpha-difluoromethylornithine (DFMO) was investigated in a human ovarian cancer cell line (NIH:OVCAR3) both in vitro and in vivo. DFMO at 5 x 10-5M, 5 x 10-4M and 1 x 10-3M concentrations showed growth inhibition of NIH:OVCAR3 cells in culture. Parallel determination of CA 125 in the culture media of these cells show significant decrease in the presence of DFMO compared to controls. Oral administration of DFMO (2% aqueous solution) to nude mice bearing intraperitoneal tumors resulted in a mean survival of 45 days (38-60) versus 25 days (20-35) for control. Both in vitro and in vivo results suggest that DFMO has potential value in the treatment of ovarian carcinoma and should be considered for clinical trials in appropriate cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0023899045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023899045&partnerID=8YFLogxK

M3 - Article

C2 - 3134241

AN - SCOPUS:0023899045

SN - 0392-2936

VL - 9

SP - 222

EP - 227

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

IS - 3

ER -

Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this